Health Care/Hospital APAC News & Press Release Distribution

Health Care/Hospital

All
Global

Transcenta Announces Presentation of Preclinical Data of TST005 at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SUZHOU, China, March 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the preclinical data...

2022-03-30 19:28 1632

FDA approves CartiHeal's Implant for the Treatment of Cartilage and Osteochondral Defects

Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint KFAR SABA, Israel, March 30, 2022 /PRNewswire/...

2022-03-30 19:00 1181

FDA approves CartiHeal's Implant for the Treatment of Cartilage and Osteochondral Defects

Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

--Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to date. Most of adverse events are grade 1 or 2. --ASC42 is a novel anti-viral candidate for HBV functional cure through inhibiting the transcription of HBV cccDNA into HBV RNA and reducing the HBV ...

2022-03-30 18:26 1748

GenScript Receives "Best Contract Development and Manufacturing Organization Award" For the Third Time in a Row

SINGAPORE, March 30, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the "Best Contract Development and Manufacturing Organization Award" on the Asia Pacific Bioprocessing Excellence Awards 2022. This marks the third consecutive year of GenScript bag...

2022-03-30 17:30 3539

BioVaxys Expands Cancer Vaccine Platform

BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine platform with BVX-0922, its autolog...

2022-03-30 16:02 2797

UNITAR Appoints Anastasios Economou, YPO Global Chairman and Founder of iGroup, to Advisory Board of the Division for Multilateral Diplomacy

GENEVA, March 30, 2022 /PRNewswire/ -- The United Nations Institute for Training and Research (UNITAR) has appointed iGroup founder andYPO's Global ChairmanAnastasios Economou to the Advisory Board of its Division for Multilateral Diplomacy. The two-year term takes effect fromJanuary 2022 to Dec...

2022-03-30 16:00 2033

New home ownership concept in Thailand's largest property development project combines home with provision of a lifetime of first-class healthcare and wellness services

'The Aspen Tree' branded residences at The Forestias to offer both a home as well as a lifetime of first-class healthcare and wellness services and healthcare insurance included in the purchase priceas part of new 'Holistic Lifetime Care' concept Up to US$ 62,000 in introductory discounts and ca...

2022-03-30 15:22 2448

New home ownership concept in Thailand's largest property development project combines home with provision of a lifetime of first-class healthcare and wellness services

Terumo and Glooko Announce Collaboration on New Solution for Diabetes Data Sharing

A Technology Integration for MEDISAFE WITHTM Insulin Patch Pump Patients to Upload Data Anytime Anywhere TOKYO, March 30, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, andGlooko , a global leader in data management, remote pa...

2022-03-30 15:00 3426

Terumo and Glooko Announce Collaboration on New Solution for Diabetes Data Sharing

GILEAD ANNOUNCES NEW DATA REINFORCING CLINICAL BENEFITS OF ITS ANTIVIRAL TREATMENTS AMONG PEOPLE LIVING WITH HEPATITIS B AND C IN ASIA (APASL 2022)

* Studies show potential improvement in risk of liver cancer in chronic hepatitis B patients after long-term antiviral treatment * Improved renal and bone parameters with tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) across multiple chronic hepatitis B patient t...

2022-03-30 11:00 1519

First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights

SUZHOU, China, March 30, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2021 and highlighted recent progress and upcoming milestones. Highlights * First product launch: In November 2021, KN035 (Envafolimab) has receiv...

2022-03-30 10:36 1917

Qiming's Portfolio Company Rendu Biotechnology Lists on STAR Market

SHANGHAI, March 30, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company Rendu Biotechnology (SESH: 688193), a leader in RNA molecular diagnostics inChina, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is...

2022-03-30 10:22 2277

Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

* This study is the third ATG-016 study to be conducted in China. * Study highlights Antengene's robust SINE programs. SHANGHAI and HONG KONG, March 30, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutic...

2022-03-30 09:00 1828

RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines

GAITHERSBURG, Md., March 30, 2022 /PRNewswire/ -- RNAimmune, Inc. (the "Company " or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximatelyUS$27 million Series A round of fina...

2022-03-30 08:31 1867

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public heal...

2022-03-30 08:05 2422

Innovent Announced 2021 Annual Results

* A Harvest Year with Product Revenue over RMB 4Bn * A Pipeline of 32 Valuable Assets with Late Stage Pipeline Potential Unveiling SAN FRANCISCO and SUZHOU, China, March 30, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that de...

2022-03-30 08:00 3329

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential

SHANGHAI, March 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) reported positive topline results from a second Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) ...

2022-03-30 08:00 2292

Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment

MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for TLX66 (90Y-besilesomab), for conditioning trea...

2022-03-29 13:34 1443

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines

- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong Pharmaceutical expects to strengthen its global business in key markets of ASEAN countries by obtaining marketing authorization in foreign countries with its branch offices SEOUL, South Korea, Marc...

2022-03-29 09:00 2011

Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor

SAN FRANCISCO and SUZHOU, China, March 29, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major d...

2022-03-29 08:10 2571

Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®

MELBOURNE, Australia and LIÈGE, Belgium, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix's prostate cancer investigational imaging product, Illuc...

2022-03-29 07:39 1618

1 ... 215 216 217218219 220 221 ... 553